Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ac-225-PSMA
- Development stage
- Phase 1
- Lead developer
- Bayer
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ac-225-PSMA is an investigational small molecule radiopharmaceutical developed by Bayer for the treatment of prostate cancer. It is designed as a Targeted Alpha Therapy (TAT), utilizing Actinium-225 (Ac-225) as a critical radioisotope. BWXT Medical supplies the Actinium-225 for this therapy. The molecule targets Prostate-Specific Membrane Antigen (PSMA), a protein overexpressed on prostate cancer cells, to deliver localized alpha radiation.
- Other names
- 225Actinium PSMAActinium-225 PSMAActinium225 PSMAActinium 225 PSMA
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on Ac-225-PSMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ac-225-PSMA.